Source comparison
MK-677 for Andropause in Men 45–55: Clinical Evidence Comparison
Healthy older adults (65+ years, n=65) 25 mg daily 12 months IGF-1 elevation and lean mass change IGF-1 increased 72% vs baseline; lean mass +1.1 kg vs placebo Sustained anabolic signaling without tachyphylaxis. Lean mass gain modest but significant in sarcope
This comparison does not assign a generated winner or score.
- Healthy older adults (65+ years, n=65)
- 25 mg daily
- 12 months
- IGF-1 elevation and lean mass change
- IGF-1 increased 72% vs baseline; lean mass +1.1 kg vs placebo
- Sustained anabolic signaling without tachyphylaxis. Lean mass gain modest but significant in sarcopenic population
- Growth hormone deficient adults (n=32)
- 8 weeks
- IGF-1 normalisation and body composition
- IGF-1 normalised in 94% of subjects; fat mass reduced 3%
- Demonstrates clinical utility in GH-deficient states, but appetite side effects led to 15% dropout rate
- Obese males (BMI 30–40, n=24)
- Resting energy expenditure and fat oxidation
- REE increased 84 kcal/day; fat oxidation unchanged
- Energy expenditure benefit exists but is insufficient to drive meaningful fat loss without caloric restriction
- Frail elderly (70+ years, n=108)
- 2 years
- Bone density and fracture incidence
- Femoral neck BMD +0.8%; no fracture reduction observed
- Long-term safety confirmed, but bone benefits minimal compared to bisphosphonates or resistance training